Zevra Therapeutics, Inc. (ZVRA) Financial Statements
Zevra Therapeutics, Inc. (ZVRA) reported trailing twelve-month revenue of $136.1M (up 119.4% year on year) and net income of $58.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $32.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ZVRAZevra Therapeutics, Inc.Follow ZVRA — free
—
Price chart with a free account
- Market cap
- 582.6M
- P/E TTM
- 10.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.8 | 13.3 | 28.7 | 10.2 | 27.5 | 23.6 | 106.5 | 136.1 | |
| Gross profit | 2.8 | — | — | 9.9 | 24.5 | 16.2 | 90.0 | 129.9 | |
| Research & development | 19.4 | 8.8 | 10.2 | 19.8 | 39.8 | 42.1 | 12.7 | 14.9 | |
| Operating income | -20.3 | -5.6 | 7.7 | -42.6 | -49.6 | -87.0 | -62.9 | 82.4 | |
| Pre-tax income | -24.5 | -12.8 | -8.5 | -26.8 | -46.0 | -90.1 | 86.7 | 69.3 | |
| Income tax | -0.0 | -0.0 | 0.0 | -0.0 | 0.0 | 15.4 | 3.4 | 11.0 | |
| Net income | -24.5 | -12.8 | -8.6 | -26.8 | -46.0 | -105.5 | 83.2 | 58.3 | |
| Diluted EPS ($) | -13.23 | -3.21 | -2.11 | — | — | -2.28 | 1.35 | 0.92 | |
| Diluted shares (mn) | — | — | 29.8 | — | — | 46.3 | 57.3 | — |
USD millions · SEC XBRL
Zevra Therapeutics, Inc. — questions
- What is Zevra Therapeutics, Inc.'s revenue?
- $136.1M over the twelve months to 2026-06-30, up 119.4% year on year, from its 10-Q and 10-K filings.
- What is Zevra Therapeutics, Inc.'s net income?
- $58.3M over the twelve months to 2026-06-30.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- $32.6M over the twelve months to 2026-06-30.
- What are Zevra Therapeutics, Inc.'s diluted earnings per share?
- $0.92 over the twelve months to 2026-06-30.
Every figure on this page comes from Zevra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.